| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3921674 | European Journal of Obstetrics & Gynecology and Reproductive Biology | 2007 | 5 Pages |
ObjectivePotassium channel openers are revealed to be a new type of antihypertensive drug. We aimed to clarify the effects of levcromakalim, an ATP-sensitive potassium channel opener, on human isolated umbilical artery (UA) and to compare them with those of nifedipine and magnesium sulphate, which are currently used in the treatment of preeclampsia (PE).Study designA total of 52 umbilical arteries, isolated immediately after delivery from 27 healthy and 25 preeclamptic pregnant women, were placed into 10-ml organ baths filled with Kreb's solution at physiological pH and temperature. The concentration-dependent relaxations in response to levcromakalim, nifedipine and magnesium sulphate were compared in vessels precontracted with serotonin (1 μmol/l).ResultsThe maximal relative relaxation responses (Emax, expressed as percentage of serotonin-induced precontraction) to magnesium sulphate, nifedipine and levcromakalim in umbilical arteries were identical in the healthy (85.06 ± 3.31, 84.80 ± 3.01 and 80.37 ± 5.32%, respectively) and preeclamptic (77.20 ± 5.30, 83.36 ± 2.37 and 79.13 ± 4.30%, respectively) groups.ConclusionLevcromakalim has a vasodilatory effect on the umbilical artery like magnesium sulphate and nifedipine, and serves as an antihypertensive potential that might be used in the treatment of preeclampsia. However, further experimental and clinical studies are needed to propose that ATP-sensitive potassium channel openers are beneficial drugs in cases of clinical preeclampsia.
